{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:09:42Z","timestamp":1793120982473,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004423","name":"WHO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherche sur le SIDA et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Few data are available on the real-world efficacy of receiving tenofovir-lamivudine-dolutegravir (-DTG) as human immunodeficiencyvirus (HIV) treatment, particularly among young people in West Africa. Here, we evaluated pharmaco-virological outcomes and resistance profiles among Togolese children and adolescents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional study was conducted in Lom\u00e9, Togo, enrolling antiretroviral-treated people with HIV aged from 18 months to 24 years. Plasma HIV-1 viral load and antiretroviral concentrations were measured. Next-generation sequencing of protease, reverse transcriptase (RT), and integrase was performed on all samples with viral loads &amp;gt;200\u2005copies\/mL. Drug resistance mutations (DRMs) were identified and interpreted using the ANRS-MIE algorithm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>264 participants were enrolled (median age, 17 years); 226 received a DTG-based regimen for a median of 20.5 months. Among them, there was virological suppression at the 200-copies\/mL threshold in 80.0% of the participants. Plasma DTG concentrations were adequate (ie, &amp;gt;640\u2005ng\/mL), suboptimal, and below the limit of quantification in 74.1%, 6.7%, and 19.2% of participants receiving DTG, respectively. Overall, viruses resistant to any of nucleoside RT inhibitors, non-NRTIs, and protease inhibitors were found in 52%, 66%, and 1.6% of participants, respectively. A major integrase inhibitor DRM was observed in 9.4% (n = 3\/32; R263K, E138A-G140A-Q148R, and N155H) of participants with a viral load &amp;gt;200\u2005copies\/mL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These first findings in a large series of adolescents in a low-income country showed a good virological response of 80% and the presence of an integrase DRM in 9.4% of virological failures, supporting the need to monitor DTG drug resistance to reduce the risk of resistance acquisition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae278","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:48:37Z","timestamp":1715788117000},"page":"144-152","source":"Crossref","is-referenced-by-count":11,"title":["Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo"],"prefix":"10.1093","volume":"80","author":[{"given":"Yao Rodion","family":"Konu","sequence":"first","affiliation":[{"name":"Facult\u00e9 des Sciences de la Sant\u00e9, D\u00e9partement de Sant\u00e9 Publique, Universit\u00e9 de Lom\u00e9 , Lom\u00e9 ,","place":["Togo"]},{"name":"Centre Africain de Recherche en Epid\u00e9miologie et en Sant\u00e9 Publique (CARESP) , Lom\u00e9 ,","place":["Togo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elom","family":"Takassi","sequence":"additional","affiliation":[{"name":"Service de P\u00e9diatrie, CHU Sylvanus Olympio, Universit\u00e9 de Lom\u00e9 , Lom\u00e9 ,","place":["Togo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie, Universit\u00e9 Paris Cit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Infections, Antimicrobials, Modeling, Evolution (IAME), UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Dapam","sequence":"additional","affiliation":[{"name":"Espoir Vie Togo , Lom\u00e9 ,","place":["Togo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wone Adama","family":"Oumarou","sequence":"additional","affiliation":[{"name":"Centre Africain de Recherche en Epid\u00e9miologie et en Sant\u00e9 Publique (CARESP) , Lom\u00e9 ,","place":["Togo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Zaidi","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Franco-Yusti","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claver A","family":"Dagnra","sequence":"additional","affiliation":[{"name":"Centre de Biologie Mol\u00e9culaire et d\u2019Immunologie, Universit\u00e9 de Lom\u00e9 , Lom\u00e9 ,","place":["Togo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Copp\u00e9e","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata Binta Tidiane","family":"Diallo","sequence":"additional","affiliation":[{"name":"Togo Office, World Health Organization , Lom\u00e9 ,","place":["Togo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier K","family":"Ekouevi","sequence":"additional","affiliation":[{"name":"Centre Africain de Recherche en Epid\u00e9miologie et en Sant\u00e9 Publique (CARESP) , Lom\u00e9 ,","place":["Togo"]},{"name":"Faculty of Health Sciences, Department of Public Health, University of Lom\u00e9, Center for Training and Research in Public Health , Lom\u00e9 ,","place":["Togo"]},{"name":"Research Institute for Sustainable Development (IRD), University of Bordeaux, INSERM, Bordeaux Population Health Centre, UMR 1219 , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, H\u00f4pital Bichat-Claude Bernard , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2025020710473421100_ciae278-B1","doi-asserted-by":"crossref","first-page":"100573","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025020710473421100_ciae278-B2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","article-title":"Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: an update on a systematic review and network meta-analysis","volume":"21","author":"Nickel","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025020710473421100_ciae278-B3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020710473421100_ciae278-B4","author":"World Health Organization"},{"key":"2025020710473421100_ciae278-B5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1","volume":"381","author":"Kouanfack","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020710473421100_ciae278-B6","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1097\/QAD.0000000000003082","article-title":"Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era","volume":"35","author":"McCluskey","year":"2021","journal-title":"AIDS"},{"key":"2025020710473421100_ciae278-B7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020710473421100_ciae278-B8","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","article-title":"Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon","volume":"7","author":"Calmy","year":"2020","journal-title":"Lancet HIV"},{"key":"2025020710473421100_ciae278-B9","doi-asserted-by":"crossref","first-page":"e25970","DOI":"10.1002\/jia2.25970","article-title":"Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review","volume":"25","author":"Townsend","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2025020710473421100_ciae278-B10","doi-asserted-by":"crossref","first-page":"ofac148","DOI":"10.1093\/ofid\/ofac148","article-title":"Dolutegravir resistance in Malawi's national HIV treatment program","volume":"9","author":"van Oosterhout","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025020710473421100_ciae278-B11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/QAD.0000000000002470","article-title":"Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa","volume":"34","author":"Salou","year":"2020","journal-title":"AIDS"},{"key":"2025020710473421100_ciae278-B12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2025020710473421100_ciae278-B13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2025020710473421100_ciae278-B14","doi-asserted-by":"crossref","first-page":"e33737","DOI":"10.1097\/MD.0000000000033737","article-title":"Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: children at high risk of virological failure due to the lowly transition in pediatrics","volume":"102","author":"Fokam","year":"2023","journal-title":"Medicine"},{"key":"2025020710473421100_ciae278-B15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jpids\/piad040","article-title":"Factors associated with viral suppression and drug resistance in children and adolescents living with HIV in care and treatment programs in Southern Tanzania","volume":"12","author":"Khamadi","year":"2023","journal-title":"J Pediatric Infect Dis"},{"key":"2025020710473421100_ciae278-B16","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2025020710473421100_ciae278-B17","doi-asserted-by":"crossref","first-page":"e0295227","DOI":"10.1371\/journal.pone.0295227","article-title":"The level of antiretroviral therapy (ART) adherence among orphan children and adolescents living with HIV\/AIDS: a systematic review and meta-analysis","volume":"19","author":"Kamau","year":"2024","journal-title":"PLoS One"},{"key":"2025020710473421100_ciae278-B18","doi-asserted-by":"crossref","first-page":"e28535","DOI":"10.1002\/jmv.28535","article-title":"Pharmaco-virological algorithm to target risk of drug resistance among a population of HIV-infected key populations in Togo","volume":"95","author":"Ferr\u00e9","year":"2023","journal-title":"J Med Virol"},{"key":"2025020710473421100_ciae278-B19","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1093\/cid\/ciaa1161","article-title":"Pretreatment and acquired antiretroviral drug resistance among persons living with HIV in four African countries","volume":"73","author":"Crowell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025020710473421100_ciae278-B20","author":"Namayanja"},{"key":"2025020710473421100_ciae278-B21","author":"Bhatt"},{"key":"2025020710473421100_ciae278-B22","author":"Hans"},{"key":"2025020710473421100_ciae278-B23","author":"Kalata"},{"key":"2025020710473421100_ciae278-B24","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae278\/58147239\/ciae278.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/144\/58147239\/ciae278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/144\/58147239\/ciae278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:48:00Z","timestamp":1738925280000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/1\/144\/7674162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae278","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,5,15]]}}}